Summary

Eligibility
for people ages 12 months to 30 years (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Official Title

A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors

Details

Keywords

Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Lymphoma, Neoplasms, Sarcoma, Rhabdomyosarcoma, Ewing Sarcoma, Alveolar Rhabdomyosarcoma, Recurrence, Elimusertib

Eligibility

Locations

  • UCSF Medical Center-Mission Bay
    San Francisco California 94158 United States
  • Children's Hospital Los Angeles
    Los Angeles California 90027 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT05071209
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
About 31 people participating
Last Updated